wherein said antisense compound is an antisense oligonucleotide which comprises at least a 10 nucleobase portion of sequence B of Figure 1.--

--39. (New) An antisense oligonucleotide or analog thereof comprising a sequence having 90% or greater identity to sequence A,B,C,D,E,F,G,H,I,J,K,L, or M of Figure 1.--

--40. (New) An antisense oligonucleotide or analog thereof comprising a sequence having 85% or greater identity to sequence A,B,C,D,E,F,G,H,I,J,K,L, or M of Figure 1.--

--41. (New) An antisense oligonucleotide or analog thereof comprising a sequence having 80% or greater identity to sequence A,B,C,D,E,F,G,H,I,J,K,L, or M of Figure 1.--

--42. (New) An antisense oligonucleotide or analog thereof comprising a sequence having 75% or greater identity to sequence A, B, C, D, E, F, G, H, I, J, K, L, or M of Figure 1.--

--43. (New) An antisense oligonucleotide or analog thereof comprising a sequence having 70% or greater identity to sequence A, B, C, D, E, F, G, H, I, J, K, L, or M of Figure 1.--

--44. (New) The antisense oligonucleotide of claim 37,38,39,40,41, 42 or 43 which comprises at least one modified internucleoside linkage.--

--45. (New) The antisense oligonucleotide of claim 44, wherein the modified internucleoside linkage is phosphorothioate linkage.--

--46. (New) The antisense oligonucleotide of claim 44, wherein the modified internucleoside linkage is a morpholino linkage.--

--47. (New) The antisense oligonucleotide of claim 37,38,39,40,41, 42 or 43, which comprises at least one modified sugar moiety.--

--48. (New) The antisense oligonucleotide of claim 37,38,39,40,41, 42 or 43, which comprises at least one modified nucleobase.--

--49. (New) The antisense oligonucleotide of claim 48, wherein the modified nucleobase is a 5-methylcytosine.--

--50. (New) The antisense oligonucleotide of claim 37,38,39,40,41, 42 or 43, which is a chimeric oligonucleotide.--

--51. (New) An antisense oligonucleotide comprising nucleotide sequence G of Figure 1.--

--52. (New) An antisense oligonucleotide comprising at least 10 contiguous nucleotides of nucleotide sequence G of Figure 1.--

--53. (New) The antisense oligonucleotide of claim 37,38,39,40,41, 42 or 43, wherein one or more of the oligonucleotide's sugars contain an -OMe group at their 2' position.--

--54. (New) The antisense oligonucleotide of claim 53, wherein substantially all the oligonucleotide's sugars contain an -Ome group at their 2' position.--

--55. (New) A method of inhibiting the expression of bcl-xl in human cells or tissues in vitro comprising contacting said cells or tissues with the antisense oligonucleotide of claim 37,38,39,40,41, 42 or 43 so that the expression of bcl-xl is inhibited.--

C1

--56. (New) A method of treating cancer, comprising administering to a patient in need of such treatment the antisense oligonucleotide of claim 37,38,39,40,41, 42 or 43.--

--57. (New) The method of claim 56, further comprising administering chemotherapy to the patient.--

--58. (New) A pharmaceutical composition comprising an effective amount of the antisense oligonucleotide or analog thereof of claim 37,38,39,40,41, 42 or 43 and a pharmaceutically acceptable carrier.--

--59. (New) A method of treating cancer, comprising administering to a patient in need of such treatment the pharmaceutical composition of claim 58.--